Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

NCT02591095 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT02591095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02591095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
Lead sponsor
Centre Francois Baclesse
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2016
Completion date
March 31, 2019
Enrollment
47 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant or refractory ovarian cancer